Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Liabilities (2021 - 2025)

Bioregenx has reported Total Liabilities over the past 5 years, most recently at $4.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 27.28% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, up 27.28%, while the annual FY2025 figure was $4.9 million, 27.28% up from the prior year.
  • Total Liabilities for Q4 2025 was $4.9 million at Bioregenx, up from $4.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $4.9 million in Q4 2025 and troughed at $101553.0 in Q1 2022.
  • A 5-year average of $2.2 million and a median of $2.9 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: increased 10.9% in 2023 and later skyrocketed 1480.07% in 2024.
  • Year by year, Total Liabilities stood at $211996.0 in 2021, then rose by 22.97% to $260691.0 in 2022, then soared by 1026.69% to $2.9 million in 2023, then soared by 32.36% to $3.9 million in 2024, then rose by 27.28% to $4.9 million in 2025.
  • Business Quant data shows Total Liabilities for BRGX at $4.9 million in Q4 2025, $4.8 million in Q3 2025, and $4.8 million in Q2 2025.